RT Journal Article
T1 Antitumor activity of bengamide ii in a panel of human and murine tumor cell lines: In vitro and in vivo determination of effectiveness against lung cancer
A1 Ortigosa-Palomo, Alba
A1 Porras Alcalá, Cristina
A1 Quiñonero, Francisco
A1 Moya-Utrera, Federico
A1 Ortiz, Raúl
A1 López-Romero, Juan Manuel
A1 Melguizo, Consolación
A1 Sarabia-García, Francisco Ramón
A1 Prados, José
K1 Pulmones - Cáncer
K1 Antineoplásicos
AB Lung cancer is the most commonly diagnosed cancer and the one that causes the most deaths worldwide, so thereis a need for therapies that improve survival rates. Products derived from marine organisms are a source of novel and potent antitumor compounds, but they present the great obstacle of their obtaining from the natural environment and the problems associated with the synthesis and biological effects of chemical analogues. In this work, a Bengamide analogue (Bengamide II) was chemically synthesized and in vitro and in vivo studies were performed to determine its antitumor activity and mechanisms of action. It was shown to have potent antiproliferative activity in lung cancer lines in 2D and 3D models. In addition, Bengamide II-treated cells showed G2/M and G0/G1 cell cycle arrest, together with a decrease in the proliferation marker Ki67. As for the mechanism of action, the treatment was associated with increased LC3-II expression and production of acidic vesicles signaling autophagy. In addition, Bengamide II treatment was associated with caspase-3 activation and DNA fragmentation related to apoptosis. Furthermore, a reduction of VEGFA expression, related to angiogenesis, was also observed. In vivo studies showed that Bengamide II markedly reduced tumor volume and metastases increasing survival. Additionally, it revealed no systemic toxicity in in vivo models at the therapeutic doses used,which is essential for its future clinical use. Taken together, the chemically synthesized bengamide analogue Bengamide II, is a promising drug for lung cancer treatment showing relevant antitumor activity and significant safety.
PB Elsevier
YR 2023
FD 2023
LK https://hdl.handle.net/10630/40452
UL https://hdl.handle.net/10630/40452
LA eng
NO Alba Ortigosa-Palomo, Cristina Porras-Alcalá, Francisco Quiñonero, Federico Moya-Utrera, Raúl Ortiz, Juan M. López-Romero, Consolación Melguizo, Francisco Sarabia, Jose Prados, Antitumor activity of bengamide ii in a panel of human and murine tumor cell lines: In vitro and in vivo determination of effectiveness against lung cancer, Biomedicine & Pharmacotherapy, Volume 168, 2023, 115789, ISSN 0753-3322, https://doi.org/10.1016/j.biopha.2023.115789
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026